<DOC>
	<DOCNO>NCT00051584</DOCNO>
	<brief_summary>This open-label , randomized phase II trial compare treatment monoclonal antibody ( mAb ) drug immunoconjugate , SGN-15 , administer weekly combination weekly Gemzar® ( Gemcitabine ) treatment Gemzar® alone . The primary objective study determine toxicity safety profile combination SGN-15 Gemzar® , estimate clinical response rate estimate duration response combination therapy administer patient advanced ovarian cancer , compare treatment Gemzar® alone .</brief_summary>
	<brief_title>Safety/Efficacy Study SGN-15 ( Antibody-Drug Conjugate ) Combined With Gemcitabine Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Brief Overview Patients must pathologically confirm ovarian cancer , advance recurrent carcinoma , fail least two , three prior therapy metastatic disease Patients must &gt; 20 % Lewisy antigen expression document immunohistochemistry LVEF &gt; 50 % echo MUGA Must platinum resistant define : Progression initial platinum therapy Progression retreatment initial platinum regimen Relapse &lt; 6 month initial therapy Brief Overview Patients prior therapy Gemzar® Cumulative anthracycline exposure &gt; 300 mg/m2 More three prior chemotherapy regimens ovarian cancer ( Retreatment Taxane/Platinum initial combination consider one regimen )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>